

**St. Joseph's/Candler
Office of Research
Oncology Trials**

Summary Trial Accrual LCRP 2003-2006

Disease Entity	Protocol Number	IRB Number	Protocol Name	Sponsor	PI	IRB Initial Approval Date	Accrual 2006	Number of Subjects Enrolled	Status
Bladder	CALGB 90104	SC-04-026	A Randomized Phase III Study Comparing Sequential Chemotherapy (AG-TP) to Cisplatin and Gemcitabine (GC) as Adjuvant Treatment after Cystectomy for Transitional Cell Carcinoma of the Bladder	CALGB	Dr. Taylor	6/15/2004	0	0	CLOSED (storage)
Bladder	S0306	SC-05-055	Phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium	SWOG	Dr. Taylor	12/20/2005	0	0	Open to Enrollment
Brain	Moffitt MCC 12672	SC-03-001	Phase II Study of Daily Low Dose Thalidomide and Temodar in Multiple Brain Metastases - Moffitt Investigator Initiated	Moffitt	Dr. Taylor	1/21/2003	0	1	CLOSED (storage)
Breast	PACCT-1 (TAILORx)	SC-06-050	Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial.	CTSU	Dr. Negrea	8/15/2006	0	0	Open to Enrollment
Breast	S0307	SC-06-039	Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer	SWOG	Dr. Taylor	6/20/2006	0	0	Open to Enrollment
Breast	ACOSOG Z1031	SC-06-038	Randomized phase III trial comparing 16 to 18 weeks of neoadjuvant exemestane (25mg daily), Letrozole (2.5mg) or anastrozole (1mg) in postmenopausal women with clinical stage II and III estrogen receptor positive breast cancer.	ACOSOG	Dr. Taylor	6/20/2006	1	1	Open to Enrollment
Breast	NSABP B36	SC-06-036	Clinical trial of adjuvant therapy comparing six cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) to four cycles of andriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer.	NSABP	Dr. Taylor	6/20/2006	3	3	Open to Enrollment
Breast	RTOG 98-04/CALGB 49801	SC-06-023	Phase III trial of observation +/- tamoxifen for good risk duct in-situ (DCIS) of the female breast	RTOG	Dr. Pablo	5/16/2006	0	0	Closed to Enrollment
Breast	CALGB 70301	SC-06-028	Quality of life, employment and informal care cost analysis in women receiving adjuvant chemotherapy for breast cancer with 0-3 positive axillary lymph nodes	CALGB	Dr. Taylor	5/16/2006	0	0	Open to Enrollment
Breast	S0347	SC-05-034	A Randomized Study of Weekly Vinorelbine (Navelbine) Alone or in Combination with Trastuzumab (Herceptin) (NSC-688089) for Patients with HER-2 Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III	CALGB	Dr. Taylor	8/16/2005	0	0	CLOSED (storage)
Breast	N9831	SC-03-012	Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel with or without Trastuzumab for Women with HER 2 Over-Expressing Node Positive Breast Cancer.	ECOG	Dr. Taylor	2/18/2003	0	5	Closed to Enrollment

**St. Joseph's/Candler
Office of Research
Oncology Trials**

Disease Entity	Protocol Number	IRB Number	Protocol Name	Sponsor	PI	IRB Initial Approval Date	Accural 2006	Number of Subjects Enrolled	Status
Breast	EGF30001	SC-04-055	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination with Paclitaxel in Subjects Previously Untreated for Advanced or Metastatic Breast Cancer	GlaxoSmithKline (GSK)	Dr. Taylor	10/19/2004	0	0	CLOSED (storage)
Breast	E2100	SC-03-013	A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer	ECOG	Dr. Taylor	2/27/2003	0	1	CLOSED (storage)
Breast	BRCA 1/2	SC-05-003	Investigation of BRCA 1/2 and Hormonal Risk Factors in African American Women with Breast Cancer	Moffitt	Dr. Taylor	2/18/2005	0	0	Open to Enrollment
Breast	NSABP B 39/RTOG 0413	SC-05-043	Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer	RTOG/NSABP	Dr. Pablo	9/20/2005	0	0	Open to Enrollment
Breast	NSABP B30	SC-03-023	3-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere and Cyclophosphamide (ATC) in Breast Cancer in Patients with Positive Axillary Lymph Nodes	NSABP	Dr. Taylor	3/18/2003	0	3	Closed to Enrollment
Breast	S0226	SC-05-033	Phase III Randomized Trial of Anastrozol Versus Anastrozole and Fulvestrant as First Line Therapy For Post Menopausal Women With Metastatic Breast Cancer	CALGB	Dr. Taylor	8/16/2005	0	1	Open to Enrollment
Breast	E4101	SC-04-019	A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) plus ZD1839 in the Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer	ECOG	Dr. Negrea	5/18/2004	0	0	Open to Enrollment
Breast	NSABP B38	SC-05-019	A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node Positive Breast Cancer: Docetaxel/Docorubicine/Cyclophosphamide (TAC): Dose-Dense (DD) DocorubicineCyclophosphamide Followed by DD Paclitaxel (DD AC-P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC-PG)	CALGB	Dr. Taylor	4/19/2005	2	4	Open to Enrollment
Breast	CALGB 49907	SC-04-21	A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil – (CMF) or Doxorubicin and Cyclophosphamide – (AC), versus Capecitabine in Women 65 Years and Older with Node Positive or High-Risk Node Negative Breast Cancer	CALGB	Dr. Taylor	5/18/2004	0	3	Open to Enrollment

**St. Joseph's/Candler
Office of Research
Oncology Trials**

Disease Entity	Protocol Number	IRB Number	Protocol Name	Sponsor	PI	IRB Initial Approval Date	Accrual 2006	Number of Subjects Enrolled	Status
Breast	CALGB/CTSU 40101	SC-03-034	Cyclophosphamide and Doxorubicin (CA 4 vs 6 cycles) versus Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Women with 0-3 Positive Axillary Lymph Nodes: A 2x2 Factorial Phase III Randomized Study	CALGB	Dr. Taylor	5/20/2003	2	5	Open to Enrollment
Breast	E1500	SC-04-027	A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy	CALGB	Dr. Geffen	7/20/2004	0	3	Closed to Enrollment
Breast	IBCSG 24-02 (SOFT)	SC-06-007	A Phase III Trial of Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Pre-menopausal Women with Endocrine Responsive Breast Cancer	International Breast Cancer Study Group	Dr. Taylor	1/17/2006	0	0	Open to Enrollment
Breast	IBCSG 25-02 (TEXT)	SC-06-008	A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Pre-menopausal Women with Endocrine Responsive Breast Cancer	International Breast Cancer Study Group	Dr. Taylor	1/17/2006	0.0	0	Open to Enrollment
Breast	MKC-101	SC-06-006	Phase II Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients with Advanced or Metastatic Breast Cancer	Millenix	Dr. Taylor	1/17/2006	1	1	Open to Enrollment
Breast	777-CLP-30		Phase III Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer	Biomed	Dr. Taylor	10/18/2005	0	0	CLOSED (storage)
Breast, Neoadjuvant	ML 18530	SC-06-024	An open-label of capecitabine (Xeloda) and docetaxel (Taxotere) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative breast cancer, plus trastuzumab (Herceptin) for HER2neu positive breast cancer.	Roche	Dr. Taylor	5/16/2006	2	2	Open to Enrollment
Breast/Colorectal	SNX-1012-CLN2-006	SC-06-025	Phase II randomized double-masked placebo controlled study to evaluate the efficacy of SNX-1012 in reducing the duration and severity of ulcerative oral mucositis in patients receiving cytotoxic chemotherapy for colorectal, breast or lung cancer.	Serenex, Inc.	Dr. Taylor	5/16/2006	7	7	Open to Enrollment
Colorectal	CLTR0105-201	SC-06-055	Multi-Center, open-label, phase 2 study of CPX-1 (Irinotecan HCL: Flouridine) Liposome injection in patients with advanced cell colorectal carcinoma	Celator Pharma.	Dr. Taylor	9/19/2006	0	0	Open to Enrollment
Colorectal	NSABP C-09	SC-06-037	Phase III clinical trial comparing oxaliplatin and capecitabine in patients with resected or ablated liver metastases from colorectal cancer	NSABP	Dr. Taylor	6/20/2006	0	0	Open to Enrollment

**St. Joseph's/Candler
Office of Research
Oncology Trials**

Disease Entity	Protocol Number	IRB Number	Protocol Name	Sponsor	PI	IRB Initial Approval Date	Accural 2006	Number of Subjects Enrolled	Status
Colon	E5202	SC-06-061	Randomized Phase III Study Comparing 5 FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxalplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers	ECOG	Dr. Taylor	10/17/2006	0	0	Open to Enrollment
Colon	OncoVAX® ASI-2005-01	SC-06-030	A randomized multi-center study of active specific immunotherapy with OncoVAX® in patients with stage II colon cancer	Intracel Resources	Dr. Hoover	5/16/2006	0	0	Open to Enrollment
Colon	MACCO-A	SC-05-029	A Multicenter Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO A)	Moffitt	Dr. Taylor	7/19/2005	0	0	Open to Enrollment
Colon	N0147	SC-04-031	A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer	NCCTG	Dr. Taylor	8/17/2004	0	5	Open to Enrollment
Colon	NSABP C-08	SC-05-049	Phase III Clinical Trial Comparing Infusional 5-FU, Leucovorin and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon	NSABP	Dr. Taylor	10/18/52005	3	3	Closed to Enrollment 10-02-06
Colon	CALGB/SWOG 80405	SC-06-009	Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab or Cetuximab (C225) or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum.	CALGB/ SWOG	Dr. Taylor	1/17/2006	0	0	Open to Enrollment
Colorectal	CA225006	SC-05-006	Phase III, Randomized, Open-Label, MultiCenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second Line Treatment in Patients with Metastatic, EGFR Positive Colorectal Carcinoma	BMS	Dr. Negrea	2/15/2005	0	0	CLOSED
Esophageal	S0414	SC-05-056	Cetuximab plus cisplatin, irinotecan and thoracic radiotherapy (RTR) for locally advacned (non-metastatic), clinically unresectable esophageal cancer: A phase II trail with molecular correlates	SWOG	Dr. Taylor	12/20/2005	0	0	Open to Enrollment
GI	S0425	SC-06-044	Neoadjuvant Chemoradiation Therapy with Oxaliplatin and Capecitabine for Patients with Surgically Resectable Gastric Cancer: A Pilot Phase II Trial with Molecular Correlates	SWOG	Dr. Taylor	7/18/2006	0	0	Open to Enrollment
GI	CALGB/CTSU 80101	SC-05-035	A Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma	CALGB	Dr. Taylor	8/16/2005	2	2	Open to Enrollment
GI	ACOSOG Z9001	SC-04-009	A Phase III Randomized Double-Blind Study of Adjuvant STI (Gleevec) Versus Placebo in Patients Following the Resection Of Primary Gastrointestinal Stromal Tumor (GIST)	CALGB/ ACOSOG	Dr. Taylor	9/17/2002 1/20/2004	0	3	Open to Enrollment

**St. Joseph's/Candler
Office of Research
Oncology Trials**

Disease Entity	Protocol Number	IRB Number	Protocol Name	Sponsor	PI	IRB Initial Approval Date	Accural 2006	Number of Subjects Enrolled	Status
Head/Neck	RTOG 0522	SC-06-035	Randomized phase III trial of concurrent accelerated radiation and cisplatin vs concurrent accelerated radiation, cisplatin and cetuximab (C225) [followed by surgery for select patients] for stage III and IV head and neck carcinoma	RTOG	Dr. Pablo	6/20/2006	0	0	Open to Enrollment
Head/Neck	RTOG 0421	SC-04-044	Phase III Trial for Locally Recurrent, Previously Irradiated Head And Neck Cancer: Concurrent Re-Irradiation and Chemotherapy Versus Chemotherapy Alone	RTOG	Dr. Pablo	9/20/2005	0	0	Open to Enrollment
Leukemia	E2997	SC-03-022	Phase III Randomized Trial of Fludarabine and Cyclophosphamide versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia	ECOG	Dr. Taylor	3/18/2003	0	1	Closed to Enrollment
Leukemia	CALGB/CTSU 10201	SC-04-034	A Phase III Study of Daunorubicin and Cytarabine +G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #588421), A BCL2 Antisense Oligodeoxynucleotide, In Previously Untreated Patients with Acute Myeloid Leukemia (AML) >60 Years	CALGB	Dr. Taylor	8/17/2004	0	2	Closed to Enrollment
Leukemia, Acute Myeloid	E2902	SC-06-004	Phase III Randomized Study of Farnesyl Transferase Inhibitor R11577 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure or Patients over age 60 in First Remission	ECOG	Dr. Taylor	1/17/2006	0	0	Open to Enrollment
Lung	RTOG 0412/SWOG S0332	SC-06-043	Phase III randomized trial of preoperative chemotherapy versus preoperative concurrent chemotherapy and throacic radiotherapy followed by surgical resection and consolidation chemotherapy in favorable prognosis patients with stage IIIA (N2) non-small cell lung cancer.	RTOG	Dr. Pablo	7/1/2006	0	0	Open to Enrollment
Lung (NSCLC)	Protocol: 11961	SC-06-060	Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorefenib (BAY-43-9006) in Chemo-naive patientients with Stage IIIB-IV Non-small Cell Lung Cancer	BAYER	Dr. Taylor	10/17/2006	0	0	Open to Enrollment
Lung	S0533	SC-06-045	A pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the addition of bevacizumab (NSC-704865) in three cohorts of patients with inoperable locally advanced stage III non-small cell lung cancer	SWOG/CTSU	Dr. Taylor	7/18/2006	0	0	Open to Enrollment
Lung	S0424	SC-06-026	Molecular epidemiology case-series study of non small-cell lung cancer in smoking and non-smoking women and men	SWOG	Dr. Taylor	5/16/2006	0	0	Open to Enrollment

**St. Joseph's/Candler
Office of Research
Oncology Trials**

Disease Entity	Protocol Number	IRB Number	Protocol Name	Sponsor	PI	IRB Initial Approval Date	Accrual 2006	Number of Subjects Enrolled	Status
Lung	10486/903 Intravenous HYCAMTIN	SC-06-021	An Open-Label, Phase II Study of Weekly Intravenous HYCAMTIN and Carboplatin as First-Line Treatment of Chemo-naïve Subjects with Extensive Disease Small Cell Lung Cancer	Glaxo, Smith, Kline	Dr. Taylor	4/18/2006	0	0	Pending
Lung	S0023	SC-04-020	A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy with ZD1839 or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer	CALGB	Dr. Taylor	5/18/2004	0	1	Closed to Enrollment
Lung	S9900	SC-03-015	Randomized phase III trial of preoperative alone or surgery plus preoperative paclitaxil/carboplatin in clinical stage IB (T2N0), II (T1-2N1T3N0) and selected (T3N1) NSCLC	SWOG	Dr. Taylor		0	0	CLOSED (storage)
Lung	RTOG 0214	SC-05-032	Phase II Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients with Locally Advanced Non-Small Cell Lung Cancer	RTOG	Dr. Pablo	8/16/2005	0	0	Open to Enrollment
Lung	E5597	SC-03-011	Cancer Prevention– Phase III Chemoprevention Trial of Selenium Supplementation in Person With Resected Stage I Non Small Cell Lung Cancer	ECOG	Dr. Taylor	2/18/2003	0	1	Open to Enrollment
Lung	Amifostine	SC-04-014	Open Label, Multicenter Trial Of Amifostine (Ethyol) In The Prevention Of Radiation-Induced Esophagitis And Pneumonitis In Patients With Measurable, Unresectable Non-Small Cell Lung Cancer .	Mediumun	Dr. Pablo		0	1	CLOSED (STORAGE)
Lung	S9925	SC-03-040	Lung Cancer Specimen Repository	CALGB	Dr. Taylor	8/19/2003	0	0	CLOSED
Lung	E1500		A Randomized, Phase II ECOG Trial of Two Dose Levels of CCI-779 in Patients with Extensive-Stage Small Cell Lung Cancer Who Have Responding or Stable Disease AFTER Induction Chemotherapy	ECOG	Dr. Taylor	3/18/2003	0	1	CLOSED
Lymphoma, Non-Hodgkins	E4402	SC-06-003	Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent non-Hodgkins Lymphoma	ECOG	Dr. Taylor	1/17/2006	0	0	Open to Enrollment
Lymphoma	S0213	SC-05-054	Pilot trial of Hyper-CVAD and Methotrexate Ara C + Rituximab in patients with previously untreated mantle cell Lymphoma	SWOG	Dr. Taylor	12/20/2005	1	1	Closed to Enrollment
Melanoma	S0508	SC-05-058	Phase II trial of combination Thalidomide plus Temozolomide in patients with metastatic malignant melanoma	SWOG	Dr. Taylor	12/20/2005	0	0	Closed to Enrollment

**St. Joseph's/Candler
Office of Research
Oncology Trials**

Disease Entity	Protocol Number	IRB Number	Protocol Name	Sponsor	PI	IRB Initial Approval Date	Accrual 2006	Number of Subjects Enrolled	Status
Melanoma	E1697	SC-03-030	Phase III Randomized Study of Four Weeks High Dose IFN-2b in Stage T3-T4 or N1 (Microscopic) Melanoma	ECOG	Dr. Taylor	4/15/2003	0	0	Open to Enrollment
Miscellaneous	RAISE Trial TRA102537	SC-06-056	Randomized, double-blind, placebo controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic idiopathic thrombocytopenic purpura	GSK	Dr. Taylor	9/19/2006	0	0	Open to Enrollment
Miscellaneous	BRAG-Onc Tumor Bank	SC-06-020	Medical College of Georgia Tumor Tissue and Serum Repository - Central Biorepository for bio-repository Alliance of Georgia-Oncology.	MCG	Dr. Patwardhan	4/18/2006	0	0	Pending
Miscellaneous	CCOP MDA 0109	SC-03-010	Stress Management Training for Patients Undergoing Radiotherapy	Moffitt	Dr. Taylor	2/18/2003	0	11	Closed to Enrollment
Miscellaneous	Thymitaq	SC-04-008	A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With Thymitaq to Patients Treated With Doxorubicin	Eximias	Dr. Taylor	1/20/2004	0	12	CLOSED (storage)
Miscellaneous	Thrombopoietin	SC-04-058	497115/003: A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (SB-497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients receiving Multiple Cycles of Chemotherapy Thrombopoietin	GlaxoSmithKline (GSK)	Dr. Taylor	11/16/2004	1	3	Open to Enrollment
Multiple Myeloma	E4A03	SC-05-028	A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma With Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders	ECOG	Dr. Taylor	7/19/2005	0	2	Closed to Enrollment pending amend to extend goal
Pancreatic	E2204	SC-06-027	An intergroup randomized phase II study of bevacizumab (NSC 704865) or cetuximab (NSC 714692) in combination with gemcitabine and in combination with chemoradiation (Capecitabine and radiation) in patients with completely resected pancreatic carcinoma	ECOG	Dr. Taylor	5/16/2006	2	2	Open to Enrollment
Pancreas	PN401	SC-02-001	An Open-label, Randomized, Controlled, Phase III, Multi-Center, Clinical Trial of PN401 With High dose 5-fluorouracil (5FU) versus Gemcitabine for Treatment of Patients With Advanced Pancreatic Cancer	Pro-Neuron, Inc.	Ray R. Maddox, PharmD	1/15/2001	0	3	Closed to Enrollment
Pancreas	E4201	SC-04-033	A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer	ECOG	Dr. Taylor	8/17/2004	0	0	CLOSED (storage)

**St. Joseph's/Candler
Office of Research
Oncology Trials**

Disease Entity	Protocol Number	IRB Number	Protocol Name	Sponsor	PI	IRB Initial Approval Date	Accrual 2006	Number of Subjects Enrolled	Status
Pancreas	GV 001.004	SC-05-047	Randomized Phase II, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer	Genvec	Dr. Taylor	10/18/2005	0	0	CLOSED
Pancreas	CALGB/CTSU 80303	SC-05-038	A Randomized Phase III Trial of Gemcitabine Plus Bevacizumab (NSC #704856 IND #7921) Versus Gemcitabine Plus Placebo in Patients with Advanced Pancreatic Cancer	CALGB	Dr. Taylor	8/16/2005	0	0	CLOSED (storage)
Prostate	RTOG 0521	SC-06-034	Phase III protocol of Androgen Suppression (AS) and 3DCRT/MRT vs. AS and 3DCRT/MRT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer	RTOG	Dr. Pablo	6/20/2006	0.0	0	Open to Enrollment
Prostate	RTOG 0232	SC-06-033	A Phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate risk prostatic cancer.	RTOG	Dr. Pablo	6/20/2006	0.0	0	Open to Enrollment
Prostate	E1899	SC-04-045	Phase III randomized trials for evaluating second line hormonal therapy (ketoconazole/hydrocortisone) vs. docetaxel/estramustine combination chemotherapy on progression free survival in asymptomatic patients with a rising psa after hormonal therapy for prostate cancer	ECOG	Dr. Taylor	9/21/2004	0	0	CLOSED (storage)
Prostate	CCOP 0002	SC-03-007	The Specific Role of Isoflavones in Reducing Prostate Cancer Risk	Moffitt	Dr. Taylor	1/21/2003	0	0	CLOSED (storage)
Prostate	CCOP 0105	SC-03-006	A Randomized Pilot Clinical Trial of the Action of Isoflavones and Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy	Moffitt	Dr. Taylor	1/21/2003	0	0	CLOSED
Prostate	CALGB/CTSU 90202	SC-05-039	A Randomized Double-Blind, Placebo Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone	CALGB	Dr. Taylor	8/16/2005	0	0	Open to Enrollment
Prostate	CALGB/CTSU 90401	SC-05-037	A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone With and Without Bevacizumab (IND #7921, NSC #704865) In Men With Hormone Refractory Prostate Cancer	CALGB	Dr. Taylor	8/16/2005	1	2	Open to Enrollment
Prostate	20050147	SC-06-005	Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone Refractory Prostate Cancer	Amgen	Dr. Mazo	1/17/2006	0	0	Open to Enrollment

**St. Joseph's/Candler
Office of Research
Oncology Trials**

Disease Entity	Protocol Number	IRB Number	Protocol Name	Sponsor	PI	IRB Initial Approval Date	Accural 2006	Number of Subjects Enrolled	Status	
Prostate	S0418	SC-05-057	Phase II Study of SB-715992 (NSC-727990, IND-70273) in Taxane-resistant Androgen-Independent Metastatic prostate cancer	SWOG	Dr. Taylor	12/20/2005	0	0	CLOSED	
Prostate	GTx G300203	SC-05-007	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy	GTx	Dr. Mazo	12/15/05	0	3	Closed to Enrollment	
Prostate	PIN	SC-05-002	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety of Toremifene Citrate for the Prevention of Prostate Cancer in Men with High Grade Prostate Intraepithelial Neoplasia (PIN)	GTx	Dr. Mazo	01/18/05	1	5	Closed to Enrollment	
Rectal	Z6041	SC-06-062	Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for uT2uN0 Rectal Cancer	ACOSOG	Dr. Taylor	10/17/2006	0	0	Open to Enrollment	
Rectal	E5204	SC-06-029	Intergroup randomized phase III study of postoperative 3 Oxaliplatin, 5-FU and Leucovorin vs. Oxaliplatin, 5-FU, Leucovorin and Bevacizumab for patients with Stage II or III rectal cancer receiving pre-operative chemoradiation	ECOG	Dr. Taylor	5/16/2006	0	0	Open to Enrollment	
Rectal	E3201	SC-04-032	Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil and Leucovorin vs 5-Fluorouracil and Leucovorin for Patients with Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil	ECOG	Dr. Taylor	8/17/2004	0	0	CLOSED (storage)	
Rectum	NSABP R-04	SC-05-036	Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine With Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-FU in the Treatment of Patients with Operable Carcinoma of the Rectum	NSABP	Dr. Taylor	8/16/2005	0	0	Open to Enrollment	
Renal	CALGB/CTSU 90206	SC-04-035	A Randomized Phase III Trial of Interferon Alfa-2b or Interferon alfa-2b Plus Bevacizumab in Patients with Advanced Renal Carcinoma	CALGB	Dr. Taylor	8/17/2004	0	0	CLOSED (storage)	
Renal	E6800	SC-04-054	A Phase II Trial Evaluating Atrasentan in Patients with Advanced Renal Cell Carcinoma	ECOG	Dr. Taylor	10/19/2004	0	0	CLOSED (storage)	
Total	Total subjects enrolled covers since program started in fall 2003.							28	102	